Wall Street analysts expect NuCana PLC (NASDAQ:NCNA) to post earnings of ($0.20) per share for the current fiscal quarter, according to Zacks. Zero analysts have provided estimates for NuCana’s earnings, with the lowest EPS estimate coming in at ($0.22) and the highest estimate coming in at ($0.17). The company is scheduled to announce its next quarterly earnings results on Wednesday, March 20th.
Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow NuCana.
NuCana (NASDAQ:NCNA) last released its quarterly earnings results on Tuesday, November 27th. The company reported ($0.10) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.16.
Several institutional investors have recently made changes to their positions in NCNA. Rothschild Investment Corp IL acquired a new position in shares of NuCana during the third quarter valued at approximately $228,000. Alps Advisors Inc. raised its holdings in shares of NuCana by 8.2% during the second quarter. Alps Advisors Inc. now owns 46,269 shares of the company’s stock valued at $879,000 after acquiring an additional 3,508 shares during the last quarter. Asymmetry Capital Management L.P. raised its holdings in shares of NuCana by 82.4% during the third quarter. Asymmetry Capital Management L.P. now owns 87,321 shares of the company’s stock valued at $2,176,000 after acquiring an additional 39,449 shares during the last quarter. Alliancebernstein L.P. raised its holdings in shares of NuCana by 16.7% during the third quarter. Alliancebernstein L.P. now owns 543,049 shares of the company’s stock valued at $13,533,000 after acquiring an additional 77,519 shares during the last quarter. Finally, Baillie Gifford & Co. raised its holdings in shares of NuCana by 26.2% during the third quarter. Baillie Gifford & Co. now owns 827,308 shares of the company’s stock valued at $20,617,000 after acquiring an additional 171,858 shares during the last quarter. 25.29% of the stock is owned by institutional investors and hedge funds.
Shares of NuCana stock opened at $16.54 on Wednesday. The stock has a market cap of $526.16 million, a price-to-earnings ratio of -15.60 and a beta of 5.94. NuCana has a 12-month low of $9.85 and a 12-month high of $32.00.
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.
Featured Article: How does a reverse stock split work?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for NuCana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NuCana and related companies with MarketBeat.com's FREE daily email newsletter.